Alembic Pharmaceuticals has announced the formal commencement of Mr. Pranav Amin’s new five-year tenure as Managing Director, effective April 1, 2026. Following shareholder approval at the 15th Annual General Meeting, Mr. Amin continues his leadership role, where he will oversee the company’s international business strategy, innovation, and global expansion efforts aimed at sustaining long-term revenue and profitability growth.
Strategic Leadership Continuity
Alembic Pharmaceuticals has confirmed that Mr. Pranav Amin has officially commenced his new term as the company’s Managing Director. The appointment, which was approved by shareholders during the 15th Annual General Meeting, secures his leadership for the next five years, effective from April 1, 2026. Mr. Amin is not subject to retirement by rotation, ensuring leadership stability for the organization.
Focus on Global Expansion
Mr. Pranav Amin currently spearheads the company’s International Business division. Under his previous tenure, the company successfully strengthened its footprint in international markets by prioritizing research and development and maintaining high-quality manufacturing standards. His vision for innovation remains a central pillar of the company’s growth strategy, with a continued commitment to driving sustained improvements in both revenue and profitability within the competitive pharmaceutical sector.
Family Governance
The leadership structure at Alembic Pharmaceuticals maintains strong continuity, with Mr. Chirayu Amin serving as the Chairman of the company. Mr. Chirayu Amin is the father of both Mr. Pranav Amin and Mr. Shaunak Amin, both of whom serve as Managing Directors for the firm, highlighting a cohesive family-led approach to corporate governance and long-term business strategy.
Source: BSE
